Brain metastases in gastroesophageal cancers—an underestimated complication

[1] Bray F(2017)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study JAMA Oncol 3 524-548

[2] Ferlay J(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[3] Soerjomataram I(2017)Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis J Gastrointest Oncol 8 148-163

[4] Siegel RL(2016)Metastatic spread in patients with gastric cancer Oncotarget 7 52307-52316

[5] Torre LA(2018)Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013) JCO 36 4009-43

[6] Jemal A(2019)Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS Ann Oncol 30 34-1235

[7] Petrelli F(2014)Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Lancet Oncol 15 1224-599

[8] Riihimäki M(2021)Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy Ann Oncol 32 590-1177

[9] Hemminki A(2012)Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data Neuro Oncol 14 1171-1521

[10] Sundquist K(2017)Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study Neuro Oncol 19 1511-6

[1] Bray F(2017)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study JAMA Oncol 3 524-548

[2] Ferlay J(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[3] Soerjomataram I(2017)Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis J Gastrointest Oncol 8 148-163

[4] Siegel RL(2016)Metastatic spread in patients with gastric cancer Oncotarget 7 52307-52316

[5] Torre LA(2018)Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013) JCO 36 4009-43

[6] Jemal A(2019)Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS Ann Oncol 30 34-1235

[7] Petrelli F(2014)Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Lancet Oncol 15 1224-599

[8] Riihimäki M(2021)Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy Ann Oncol 32 590-1177

[9] Hemminki A(2012)Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data Neuro Oncol 14 1171-1521

[10] Sundquist K(2017)Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study Neuro Oncol 19 1511-6